Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lidocaine/prilocaine (Senstend®) cannot be endorsed for use within NHS Wales for the treatment of primary premature ejaculation in adult men |
||
|
||
Medicine details |
||
| Medicine name | lidocaine / prilocaine (Senstend®) | |
| Formulation | 150 / 50 mg/ml cutaneous solution | |
| Reference number | 4384 | |
| Indication | For the treatment of primary premature ejaculation in adult men |
|
| Company | Plethora Solutions Holdings PLC | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 16/06/2020 | |